Shin Fukudo

List of Publications by Year in Descending Order

135 papers	5,426 citations	39 h-index	71 g-index
143 ext. papers	6,569 ext. citations	5.7 avg, IF	5.62 L-index

#	Paper	IF	Citations
135	Histamine Neuroimaging in Stress-Related Disorders.. *Current Topics in Behavioral Neurosciences*, **2022**, 1	3.4	
134	A Questionnaire-Based Survey on the Impact of the COVID-19 Pandemic on Gastrointestinal Endoscopy in Asia. *Digestion*, **2021**, 1-15	3.6	3
133	Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	11
132	Concordant pattern of the HPA axis response to visceral stimulation and CRH administration. *Neuroscience Research*, **2021**, 168, 32-40	2.9	0
131	Modification of rectal function and emotion by repetitive transcranial magnetic stimulation in humans. *Neuroscience Research*, **2021**, 168, 54-63	2.9	2
130	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. *Gastroenterology*, **2021**, 160, 99-114.e3	13.3	285
129	Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 538-546.e8	6.9	9
128	Eating Disorder Neuroimaging Initiative (EDNI): a multicentre prospective cohort study protocol for elucidating the neural effects of cognitive-behavioural therapy for eating disorders. *BMJ Open*, **2021**, 11, e042685	3	1
127	Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. *Journal of Gastroenterology*, **2021**, 56, 193-217	6.9	22
126	Oxytocin antagonist induced visceral pain and corticotropin-releasing hormone neuronal activation in the central nucleus of the amygdala during colorectal distention in mice. *Neuroscience Research*, **2021**, 168, 41-53	2.9	2
125	Hybrid Cognitive Behavioral Therapy With Interoceptive Exposure for Irritable Bowel Syndrome: A Feasibility Study. *Frontiers in Psychiatry*, **2021**, 12, 673939	5	1
124	Rehabilitation Medicine for Abnormal Visceral Sensitivity in Irritable Bowel Syndrome(IBS). *The Japanese Journal of Rehabilitation Medicine*, **2021**, 58, 1383-1390	0	
123	The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: An observational study. *PLoS ONE*, **2020**, 15, e0234089	3.7	4
122	Imaging Brain Mechanisms of Functional Somatic Syndromes: Potential as a Biomarker?. *Tohoku Journal of Experimental Medicine*, **2020**, 250, 137-152	2.4	4
121	Effectiveness of enhanced cognitive behavior therapy for bulimia nervosa in Japan: a randomized controlled trial protocol. *BioPsychoSocial Medicine*, **2020**, 14, 2	2.8	1
120	Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 430-441	6.1	4
119	Resting state functional connectivity of the pain matrix and default mode network in irritable bowel syndrome: a graph theoretical analysis. *Scientific Reports*, **2020**, 10, 11015	4.9	5

118	Insula Activity to Visceral Stimulation and Endocrine Stress Responses as Associated With Alexithymia in Patients With Irritable Bowel Syndrome. *Psychosomatic Medicine*, **2020**, 82, 29-38	3.7	9
117	Common and distinct neural representations of aversive somatic and visceral stimulation in healthy individuals. *Nature Communications*, **2020**, 11, 5939	17.4	15
116	Clinical Usefulness of Endoscopy, Barium Fluoroscopy, and Chest Computed Tomography for the Correct Diagnosis of Achalasia. *Internal Medicine*, **2020**, 59, 323-328	1.1	8
115	The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: An observational study **2020**, 15, e0234089		
114	The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: An observational study **2020**, 15, e0234089		
113	The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: An observational study **2020**, 15, e0234089		
112	The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: An observational study **2020**, 15, e0234089		
111	The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: An observational study **2020**, 15, e0234089		
110	The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: An observational study **2020**, 15, e0234089		
109	Letter: placebo run-in for IBS clinical trials - is it useful? AuthorsSreply. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 1239-1240	6.1	
108	Lewy body constipation. *Journal of the Anus, Rectum and Colon*, **2019**, 3, 10-17	3.7	15
107	Cognitive behavioral therapy with interoceptive exposure and complementary video materials for irritable bowel syndrome (IBS): protocol for a multicenter randomized controlled trial in Japan. *BioPsychoSocial Medicine*, **2019**, 13, 14	2.8	5
106	Parasympathetic activity correlates with subjective and brain responses to rectal distension in healthy subjects but not in non-constipated patients with irritable bowel syndrome. *Scientific Reports*, **2019**, 9, 7358	4.9	7
105	Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients With Functional Constipation. *Journal of Neurogastroenterology and Motility*, **2019**, 25, 332-333	4.4	
104	Second Asian Consensus on Irritable Bowel Syndrome. *Journal of Neurogastroenterology and Motility*, **2019**, 25, 343-362	4.4	31
103	Future Possibility of Mizagliflozin on Functional Constipation and/or Irritable Bowel Syndrome With Constipation. *Gastroenterology*, **2019**, 157, 898-899	13.3	1
102	VII. How to Treat Chronic Constipation with Intestinal Secretagogues or Inhibitor of Ileal Bile Acid Transporter. *The Journal of the Japanese Society of Internal Medicine*, **2019**, 108, 46-54	0	
101	Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study. *Journal of Gastroenterology*, **2019**, 54, 530-540	6.9	5

100	High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan. *Neurogastroenterology and Motility*, **2019**, 31, e13487	4	12
99	Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study. *Neurogastroenterology and Motility*, **2018**, 30, e13275	4	16
98	Randomized, double-blind, placebo-controlled study vs data in the daily practice using linaclotide in patients with irritable bowel syndrome with constipation. *Neurogastroenterology and Motility*, **2018**, 30, e13363	4	0
97	Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 603-613	18.8	20
96	Effect of attention bias modification on event-related potentials in patients with irritable bowel syndrome: A preliminary brain function and psycho-behavioral study. *Neurogastroenterology and Motility*, **2018**, 30, e13402	4	4
95	Association Between Alexithymia and Functional Gastrointestinal Disorders. *Frontiers in Psychology*, **2018**, 9, 599	3.4	14
94	Understanding Neurogastroenterology From Neuroimaging Perspective: A Comprehensive Review of Functional and Structural Brain Imaging in Functional Gastrointestinal Disorders. *Journal of Neurogastroenterology and Motility*, **2018**, 24, 512-527	4.4	38
93	Relationship between sympathoadrenal and pituitary-adrenal response during colorectal distention in the presence of corticotropin-releasing hormone in patients with irritable bowel syndrome and healthy controls. *PLoS ONE*, **2018**, 13, e0199698	3.7	5
92	Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study. *Neurogastroenterology and Motility*, **2018**, 30, e13442	4	9
91	Role of Brain-Gut Axis in Irritable Bowel Syndrome. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, SY71-2	0	
90	Influence of the requirement for abdominal pain in the diagnosis of irritable bowel syndrome with constipation (IBS-C) under the Rome IV criteria using data from a large Japanese population-based internet survey. *BioPsychoSocial Medicine*, **2018**, 12, 18	2.8	8
89	Impact of symptoms by gender and age in Japanese subjects with irritable bowel syndrome with constipation (IBS-C): a large population-based internet survey. *BioPsychoSocial Medicine*, **2018**, 12, 12	2.8	9
88	A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan. *Neurogastroenterology and Motility*, **2018**, 30, e13444	4	14
87	The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. *Gut*, **2017**, 66, 1075-1082	19.2	242
86	Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study. *Neurogastroenterology and Motility*, **2017**, 29, e13023	4	11
85	Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea. *BioPsychoSocial Medicine*, **2017**, 11, 8	2.8	3
84	Effect of attention bias modification on brain function and anxiety in patients with irritable bowel syndrome: A preliminary electroencephalogram and psycho-behavioral study. *Neurogastroenterology and Motility*, **2017**, 29, e13131	4	4
83	Influence of Uncertain Anticipation on Brain Responses to Aversive Rectal Distension in Patients With Irritable Bowel Syndrome. *Psychosomatic Medicine*, **2017**, 79, 988-999	3.7	18

82	Linaclotide is Effective and Safe for Patients with Irritable Bowel Syndrome with Constipation in Japan: A Phase III Randomized, Double-Blind, and Placebo-Controlled and Long-Term Extension Study. *Gastroenterology*, **2017**, 152, S714	13.3	2
81	Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea. *BioPsychoSocial Medicine*, **2017**, 11, 7	2.8	2
80	Development of a Japanese version of the Somatic Symptom Scale-8: Psychometric validity and internal consistency. *General Hospital Psychiatry*, **2017**, 45, 7-11	5.6	22
79	Altered brain and gut responses to corticotropin-releasing hormone (CRH) in patients with irritable bowel syndrome. *Scientific Reports*, **2017**, 7, 12425	4.9	44
78	Irritable bowel syndrome. *Nature Reviews Disease Primers*, **2016**, 2, 16014	51.1	429
77	Abdominal bloating is the most bothersome symptom in irritable bowel syndrome with constipation (IBS-C): a large population-based Internet survey in Japan. *BioPsychoSocial Medicine*, **2016**, 10, 19	2.8	32
76	Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. *Journal of Gastroenterology*, **2016**, 51, 874-82	6.9	16
75	Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. *Gastroenterology*, **2016**, 150, 358-66.e8	13.3	69
74	Corticotropin-Releasing Hormone Receptor 2 Gene Variants in Irritable Bowel Syndrome. *PLoS ONE* , **2016**, 11, e0147817	3.7	17
73	Associations between Single-Nucleotide Polymorphisms in Corticotropin-Releasing Hormone-Related Genes and Irritable Bowel Syndrome. *PLoS ONE*, **2016**, 11, e0149322	3.7	11
72	Dai-Kenchu-To, a Herbal Medicine, Attenuates Colorectal Distention-induced Visceromotor Responses in Rats. *Journal of Neurogastroenterology and Motility*, **2016**, 22, 686-693	4.4	5
71	Differential Activation in Amygdala and Plasma Noradrenaline during Colorectal Distention by Administration of Corticotropin-Releasing Hormone between Healthy Individuals and Patients with Irritable Bowel Syndrome. *PLoS ONE*, **2016**, 11, e0157347	3.7	20
70	Multicultural Aspects in Functional Gastrointestinal Disorders (FGIDs). *Gastroenterology*, **2016**,	13.3	34
69	Survey of clinical practice for irritable bowel syndrome in East asian countries. *Digestion*, **2015**, 91, 99-109	3.6	13
68	Mo1281 Optimal Dose of Ramosetron in Female Patients With Irritable Bowel Syndrome With Diarrhea: A Randomized, Placebo-Controlled Phase II Trial. *Gastroenterology*, **2015**, 148, S-659	13.3	2
67	Injection of corticotropin-releasing hormone into the amygdala aggravates visceral nociception and induces noradrenaline release in rats. *Neurogastroenterology and Motility*, **2015**, 27, 30-9	4	39
66	Pharmacological and psychosomatic treatments for an elderly patient with severe nausea and vomiting in reaction to postoperative stress. *Clinical Journal of Gastroenterology*, **2015**, 8, 275-9	1.1	0
65	Reply: To PMID 25158925. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1379	6.9	

64	Evidence-based clinical practice guidelines for irritable bowel syndrome. *Journal of Gastroenterology*, **2015**, 50, 11-30	6.9	84
63	Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 294-301.e5	6.9	68
62	Effect of 5-hydroxytryptamine receptor 4 agonist mosapride on human gastric accommodation. *Neurogastroenterology and Motility*, **2015**, 27, 1303-9	4	13
61	Maladjustment to Academic Life and Employment Anxiety in University Students with Irritable Bowel Syndrome. *PLoS ONE*, **2015**, 10, e0129345	3.7	9
60	Validity and Reliability of the Japanese Version of the Rome III Diagnostic Questionnaire for Irritable Bowel Syndrome and Functional Dyspepsia. *Journal of Neurogastroenterology and Motility*, **2015**, 21, 537-44	4.4	28
59	Evaluation of Kampo medicine in the clinical practice guideline for irritable bowel syndrome. *Journal of Gastroenterology*, **2015**, 50, 817-8	6.9	
58	Gastrointestinal symptoms and disorders in patients with eating disorders. *Clinical Journal of Gastroenterology*, **2015**, 8, 255-63	1.1	69
57	Serotonin Transporter Gene Polymorphism Modulates Activity and Connectivity within an Emotional Arousal Network of Healthy Men during an Aversive Visceral Stimulus. *PLoS ONE*, **2015**, 10, e0123183	3.7	9
56	Epidemiology of irritable bowel syndrome. *Annals of Gastroenterology*, **2015**, 28, 158-159	2.2	26
55	Gastrointestinal specific anxiety in irritable bowel syndrome: validation of the Japanese version of the visceral sensitivity index for university students. *BioPsychoSocial Medicine*, **2014**, 8, 10	2.8	22
54	Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 953-9.e4	6.9	58
53	The alexithymic brain: the neural pathways linking alexithymia to physical disorders. *BioPsychoSocial Medicine*, **2013**, 7, 1	2.8	98
52	Stress and visceral pain: focusing on irritable bowel syndrome. *Pain*, **2013**, 154 Suppl 1, S63-S70	8	51
51	Sex differences in brain response to anticipated and experienced visceral pain in healthy subjects. *American Journal of Physiology - Renal Physiology*, **2013**, 304, G687-99	5.1	43
50	Effects of preceding stimulation on brain activation in response to colonic distention in humans. *Psychosomatic Medicine*, **2013**, 75, 453-62	3.7	12
49	Neural basis of impaired cognitive flexibility in patients with anorexia nervosa. *PLoS ONE*, **2013**, 8, e61108	3.7	73
48	Effects of personality traits on the manifestations of irritable bowel syndrome. *BioPsychoSocial Medicine*, **2012**, 6, 20	2.8	18
47	Altered cognitive function of prefrontal cortex during error feedback in patients with irritable bowel syndrome, based on FMRI and dynamic causal modeling. *Gastroenterology*, **2012**, 143, 1188-1198	13.3	67

46	Management and pathophysiology of functional gastrointestinal disorders. *Digestion*, **2012**, 85, 85-9	3.6	10
45	Enhanced auditory brainstem response and parental bonding style in children with gastrointestinal symptoms. *PLoS ONE*, **2012**, 7, e32913	3.7	6
44	Corticotropin-releasing hormone receptor 1 gene variants in irritable bowel syndrome. *PLoS ONE*, **2012**, 7, e42450	3.7	19
43	Neural substrates of decision making as measured with the Iowa Gambling Task in men with alexithymia. *Psychosomatic Medicine*, **2011**, 73, 588-97	3.7	23
42	Gene, environment, and brain-gut interactions in irritable bowel syndrome. *Journal of Gastroenterology and Hepatology (Australia)*, **2011**, 26 Suppl 3, 110-5	4	61
41	Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. *Neurogastroenterology and Motility*, **2011**, 23, 544-e205	4	68
40	Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome. *Neurogastroenterology and Motility*, **2011**, 23, 754-e332	4	35
39	Effect of repetitive transcranial magnetic stimulation on rectal function and emotion in humans. *Journal of Gastroenterology*, **2011**, 46, 1071-80	6.9	4
38	Lifestyle and psychological factors related to irritable bowel syndrome in nursing and medical school students. *Journal of Gastroenterology*, **2011**, 46, 1403-10	6.9	63
37	A neurological approach to biopsychosocial medicine: Lessons from irritable bowel syndrome. *BioPsychoSocial Medicine*, **2011**, 5, 1	2.8	7
36	Differential responding of autonomic function to histamine H□antagonism in irritable bowel syndrome. *Neurogastroenterology and Motility*, **2010**, 22, 1284-91, e335	4	10
35	Asian consensus on irritable bowel syndrome. *Journal of Gastroenterology and Hepatology (Australia)*, **2010**, 25, 1189-205	4	122
34	Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. *Neurogastroenterology and Motility*, **2010**, 22, 512-9, e114-5	4	266
33	OC-067 Phenotyping visceral pain in humans using brain imaging. *Gut*, **2010**, 59, A28.1-A28	19.2	
32	Effect of autogenic training on general improvement in patients with irritable bowel syndrome: a randomized controlled trial. *Applied Psychophysiology Biofeedback*, **2010**, 35, 189-98	3.4	41
31	Increased brain histamine H1 receptor binding in patients with anorexia nervosa. *Biological Psychiatry*, **2009**, 65, 329-35	7.9	39
30	Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. *NeuroImage*, **2009**, 47, 946-51	7.9	69
29	Corticotropin-releasing hormone receptor 1 antagonist blocks colonic hypersensitivity induced by a combination of inflammation and repetitive colorectal distension. *Neurogastroenterology and Motility*, **2008**, 20, 1147-56	4	38

28	Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. *American Journal of Gastroenterology*, **2008**, 103, 2550-61	0.7	121
27	High prevalence of irritable bowel syndrome in medical outpatients in Japan. *Journal of Clinical Gastroenterology*, **2008**, 42, 1010-6	3	38
26	Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). *BioPsychoSocial Medicine*, **2007**, 1, 6	2.8	48
25	Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome. *Neurogastroenterology and Motility*, **2007**, 19, 471-83	4	40
24	Role of histaminergic neurons in hypnotic modulation of brain processing of visceral perception. *Neurogastroenterology and Motility*, **2007**, 19, 831-8	4	17
23	Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. *Journal of Gastroenterology*, **2007**, 42 Suppl 17, 48-51	6.9	101
22	Correlation between alexithymia and hypersensitivity to visceral stimulation in human. *Pain*, **2007**, 132, 252-263	8	90
21	Can modulating corticotropin releasing hormone receptors alter visceral sensitivity?. *Gut*, **2006**, 55, 146-8	9.2	16
20	Gender, age, society, culture, and the patientS perspective in the functional gastrointestinal disorders. *Gastroenterology*, **2006**, 130, 1435-46	13.3	263
19	Gender difference in association between polymorphism of serotonin transporter gene regulatory region and anxiety. *Journal of Psychosomatic Research*, **2006**, 60, 91-7	4.1	70
18	Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index. *Journal of Gastroenterology*, **2006**, 41, 491-4	6.9	41
17	Corticotropin-releasing hormone receptor 1 antagonist blocks brain-gut activation induced by colonic distention in rats. *Gastroenterology*, **2005**, 129, 1533-43	13.3	49
16	Classical conditioned response of rectosigmoid motility and regional cerebral activity in humans. *Neurogastroenterology and Motility*, **2005**, 17, 705-13	4	8
15	Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. *Gut*, **2004**, 53, 958-64	19.2	206
14	Brain activity during distention of the descending colon in humans. *Neurogastroenterology and Motility*, **2004**, 16, 299-309	4	39
13	Decreased histamine H1 receptor binding in the brain of depressed patients. *European Journal of Neuroscience*, **2004**, 20, 803-10	3.5	61
12	Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress. *Digestive Diseases and Sciences*, **2004**, 49, 1046-53	4	106
11	Specific brain processing of facial expressions in people with alexithymia: an H2 15O-PET study. *Brain*, **2003**, 126, 1474-84	11.2	179

10	Colorectal distention induces hippocampal noradrenaline release in rats: an in vivo microdialysis study. *Brain Research*, **2002**, 947, 146-9	3.7	21
9	Exaggerated motility of the descending colon with repetitive distention of the sigmoid colon in patients with irritable bowel syndrome. *Journal of Gastroenterology*, **2002**, 37 Suppl 14, 145-50	6.9	40
8	Food-deprived activity stress decreased the activity of the histaminergic neuron system in rats. *Brain Research*, **2001**, 891, 32-41	3.7	35
7	Exaggerated visceresensory evokad potentials in irritable bowel syndrome. *Gastroenterology*, **2001**, 120, A750	13.3	2
6	Exaggerated visceresensory evokad potentials in irritable bowel syndrome. *Gastroenterology*, **2001**, 120, A750-A750	13.3	2
5	Abnormal visceral perception in patients with functional dyspepsia: use of cerebral potentials evoked by electrical stimulation of the oesophagus. *Neurogastroenterology and Motility*, **2000**, 12, 87-94	4	13
4	Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. *Gut*, **1998**, 42, 845-9	19.2	297
3	Involvement of the 5-HT3 receptor in CRH-induce defecation in rats. *American Journal of Physiology - Renal Physiology*, **1998**, 274, G827-31	5.1	38
2	Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome. A preliminary study. *Journal of Clinical Gastroenterology*, **1993**, 17, 133-41	3	91
1	Colonic motility, autonomic function, and gastrointestinal hormones under psychological stress on irritable bowel syndrome. *Tohoku Journal of Experimental Medicine*, **1987**, 151, 373-85	2.4	91